Loading clinical trials...
Loading clinical trials...
Phase III Postneoadjuvant Study Evaluating Sacituzumab Govitecan, an Antibody Drug Conjugate in Primary HER2-negative Breast Cancer Patients With High Relapse Risk After Standard Neoadjuvant Treatment - SASCIA
Conditions
Interventions
Capecitabine
Carboplatin
+2 more
Locations
163
Austria
MUG - Univ.-Klinik f. Frauenheilkunde u. Geburtshilfe Graz
Graz, Austria
MUG - Univ.-Klinik f. Innere Medizin Graz
Graz, Austria
MUI - Univ. Klinik f. Frauenheilkunde Innsbruck
Innsbruck, Austria
Ordensklinikum Linz GmbH - BHS
Linz, Austria
TumorZentrum Kepler Uniklinikum Linz
Linz, Austria
LKH Salzburg - PMU
Salzburg, Austria
Start Date
October 28, 2020
Primary Completion Date
March 30, 2027
Completion Date
March 30, 2029
Last Updated
April 22, 2026
NCT06681064
NCT05005403
NCT05467891
NCT06547840
NCT05660083
NCT07483307
Lead Sponsor
GBG Forschungs GmbH
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions